Penghui Zhou1, Xincheng Zheng, Huiming Zhang, Yang Liu, Pan Zheng. 1. Department of Surgery and Pathology, University of Michigan Medical Center, Program of Molecular Mechanism of Diseases and Comprehensive Cancer Center, Ann Arbor, Michigan 48109, USA.
Abstract
PURPOSE: In prostate cancer-bearing host, regulatory T (Treg) cells restrain activity of tumor antigen-specific T cells. Because B7:CD28 interactions are needed for both function of CD4+CD25+ Treg cells and CD8+ effective T cells, targeting this pathway may help to overcome the immunotherapy barriers. EXPERIMENTAL DESIGN: The anti-B7-1/B7-2 monoclonal antibodies were administered to a transgenic mouse model of prostate cancer (TRAMP) ectopically expressing SV40 large T antigen in different tumor development stages for prevention and therapy of prostate cancer. The treatment was also tested in treating transplanted MC38 colon adenocarcinoma in mice. RESULTS: Here, we showed that short-term administration of anti-B7-1/B7-2 monoclonal antibodies in TRAMP mice leads to significant inhibited primary tumor growth and the size of metastatic lesions. The treatment is effective to inhibit MC38 colon cancer growth. Correspondingly, this treatment results in a transient reduction of Treg in both thymus and the periphery. In vivo cytotoxicity assay revealed T antigen-specific CTL effectors in anti-B7-treated but not control IgG-treated TRAMP mice. CONCLUSIONS: Transient blockade of B7-1/B7-2 alters the balance between Treg and cancer-reactive T cells to enhance cancer immunotherapy.
PURPOSE: In prostate cancer-bearing host, regulatory T (Treg) cells restrain activity of tumor antigen-specific T cells. Because B7:CD28 interactions are needed for both function of CD4+CD25+ Treg cells and CD8+ effective T cells, targeting this pathway may help to overcome the immunotherapy barriers. EXPERIMENTAL DESIGN: The anti-B7-1/B7-2 monoclonal antibodies were administered to a transgenicmouse model of prostate cancer (TRAMP) ectopically expressing SV40 large T antigen in different tumor development stages for prevention and therapy of prostate cancer. The treatment was also tested in treating transplanted MC38 colon adenocarcinoma in mice. RESULTS: Here, we showed that short-term administration of anti-B7-1/B7-2 monoclonal antibodies in TRAMPmice leads to significant inhibited primary tumor growth and the size of metastatic lesions. The treatment is effective to inhibit MC38 colon cancer growth. Correspondingly, this treatment results in a transient reduction of Treg in both thymus and the periphery. In vivo cytotoxicity assay revealed T antigen-specific CTL effectors in anti-B7-treated but not control IgG-treated TRAMPmice. CONCLUSIONS: Transient blockade of B7-1/B7-2 alters the balance between Treg and cancer-reactive T cells to enhance cancer immunotherapy.
Authors: Elena Degl'Innocenti; Matteo Grioni; Giusy Capuano; Elena Jachetti; Massimo Freschi; Maria T S Bertilaccio; Rodrigo Hess-Michelini; Claudio Doglioni; Matteo Bellone Journal: Cancer Res Date: 2008-01-01 Impact factor: 12.701
Authors: Jayne S Sutherland; Gabrielle L Goldberg; Maree V Hammett; Adam P Uldrich; Stuart P Berzins; Tracy S Heng; Bruce R Blazar; Jeremy L Millar; Mark A Malin; Ann P Chidgey; Richard L Boyd Journal: J Immunol Date: 2005-08-15 Impact factor: 5.422
Authors: Katharina Lahl; Christoph Loddenkemper; Cathy Drouin; Jennifer Freyer; Jon Arnason; Gérard Eberl; Alf Hamann; Hermann Wagner; Jochen Huehn; Tim Sparwasser Journal: J Exp Med Date: 2007-01-02 Impact factor: 14.307
Authors: James P Scott-Browne; Shahin Shafiani; Glady's Tucker-Heard; Kumiko Ishida-Tsubota; Jason D Fontenot; Alexander Y Rudensky; Michael J Bevan; Kevin B Urdahl Journal: J Exp Med Date: 2007-08-20 Impact factor: 14.307
Authors: Jianmin Zhu; Jin-Qing Liu; Min Shi; Xinhua Cheng; Miao Ding; Jianchao C Zhang; Jonathan P Davis; Sanjay Varikuti; Abhay R Satoskar; Lanchun Lu; Xueliang Pan; Pan Zheng; Yang Liu; Xue-Feng Bai Journal: JCI Insight Date: 2018-04-05
Authors: S Peter Bak; Mike Stein Barnkob; Ailin Bai; Eileen M Higham; K Dane Wittrup; Jianzhu Chen Journal: J Immunol Date: 2012-07-13 Impact factor: 5.422